Rotondi Mario, Mazziotti Gherardo, Sorvillo Francesca, Piscopo Marco, Cioffi Michele, Amato Giovanni, Carella Carlo
Department of Clinical and Experimental Medicine F. Magrassi and A. Lanzara, Second University of Naples, 80121 Naples, Italy.
Eur J Endocrinol. 2004 Dec;151(6):695-700. doi: 10.1530/eje.0.1510695.
To compare the effects of pregnancy on the serum free thyroxine (FT4) levels in two cohorts of primary hypothyroid women treated with different levothyroxine (L-T4) doses before gestation.
Twenty-five women with compensated hypothyroidism of different aetiology (thyroidectomized and Hashimoto's thyroiditis) were enrolled in this prospective study. The women were receiving substitutive doses of L-T4 and were anticipating pregnancy. They were assigned to two groups: 14 patients (group I) were switched to partially suppressive treatment while 11 patients (group II) continued the same therapeutic regimen.
Pre-conceptional thyroid function evaluation demonstrated significantly higher FT4 and lower TSH in group I (P<0.001, for both hormones) and comparable free 3,5,3'-triiodothyronine (FT3) levels. The first post-conception thyroid function evaluation occurred at a median time of 6 (5-8) and 7 (5-9) weeks of gestation, for groups I and II respectively (P<0.05); all women in group I showed adequate serum FT4 levels while three patients in group II showed low-normal FT4 levels and one case was below normal levels. Statistical analysis demonstrated significantly higher frequencies (0% vs 36.4%; P<0.05) of low-normal FT4 levels in patients receiving substitutive doses of L-T4. None of the Hashimoto's-affected patients showed low or low-normal serum FT4 levels regardless of their therapeutic regimen.
Our results suggest that in hypothyroid women anticipating pregnancy (with serum TSH in the lower quartile of normal range), the pre-conception adjustment of L-T4 doses may result in adequate maternal thyroid function up to the first post-conception evaluation. The procedure seems safe and inexpensive; it may be a worthwhile treatment, at least in thyroidectomized women, in view of the well-known potential effects of even marginal maternal thyroid hypofunction on the subsequent IQ of the progeny.
比较妊娠对两组孕前接受不同左甲状腺素(L-T4)剂量治疗的原发性甲状腺功能减退女性血清游离甲状腺素(FT4)水平的影响。
25例不同病因(甲状腺切除术后和桥本甲状腺炎)的代偿性甲状腺功能减退女性纳入本前瞻性研究。这些女性正在接受L-T4替代剂量治疗并计划怀孕。她们被分为两组:14例患者(I组)改为部分抑制性治疗,11例患者(II组)继续相同的治疗方案。
孕前甲状腺功能评估显示,I组的FT4显著升高,TSH显著降低(两种激素均P<0.001),游离三碘甲状腺原氨酸(FT3)水平相当。I组和II组孕后首次甲状腺功能评估的中位时间分别为妊娠6(5-8)周和7(5-9)周(P<0.05);I组所有女性血清FT4水平均正常,而II组3例患者FT4水平略低于正常,1例低于正常水平。统计分析显示,接受L-T4替代剂量治疗的患者中,FT4水平略低于正常的频率显著更高(0%对36.4%;P<0.05)。无论治疗方案如何,受桥本甲状腺炎影响的患者均未出现血清FT4水平低或略低于正常的情况。
我们的结果表明,对于计划怀孕的甲状腺功能减退女性(血清TSH在正常范围的下四分位数),孕前调整L-T4剂量可能使孕后首次评估前的母体甲状腺功能正常。该方法似乎安全且成本低廉;鉴于即使是轻微的母体甲状腺功能减退对后代后续智商的潜在影响,至少对于甲状腺切除术后的女性而言,这可能是一种值得的治疗方法。